Toxic epidermal necrolysis in children: Medical, surgical, and ophthalmologic considerations

Journal of Burn Care and Research

Volumn 30, Issue 3, 2009, Pages 437-449

  Goyal, Sunali ^a   Gupta, Punkaj ^b   Ryan, Colleen M ^c   Kazlas, Melanie ^d   Noviski, Natan ^b   Sheridan, Robert L ^c  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Shriners Burns Hospital for Children   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ARTIFICIAL TEAR; BACITRACIN; BENZODIAZEPINE; CHLORMEZANONE; COPPER SULFATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IBUPROFEN; IMMUNOGLOBULIN; INFLUENZA VACCINE; LIDOCAINE; MOUTHWASH; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTOXIFYLLINE; PROPYLTHIOURACIL; PYRITIDIUM BROMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SILVER NITRATE; SULFADIAZINE SILVER; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; THALIDOMIDE; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; AUTOIMMUNE DISEASE; BODY TEMPERATURE; CLINICAL FEATURE; CONJUNCTIVA DISEASE; CORNEA DISEASE; CORTICOSTEROID THERAPY; DERMOEPIDERMAL JUNCTION; DIFFERENTIAL DIAGNOSIS; DISEASE SURVEILLANCE; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; DRY EYE; EARLY DIAGNOSIS; ELECTROLYTE BALANCE; EYE DISEASE; EYELID DISEASE; FEVER; FLUID BALANCE; HEAT LOSS; HUMAN; IDIOPATHIC DISEASE; INFLUENZA; LEUKOPENIA; MORTALITY; MUCOSA; NASOGASTRIC TUBE; NEUTROPENIA; NUTRITIONAL SUPPORT; PAIN; PATHOPHYSIOLOGY; PLASMAPHERESIS; REVIEW; REYE SYNDROME; SEPSIS; SKIN EPITHELIUM; TOXIC EPIDERMAL NECROLYSIS; VIRUS INFECTION; VISUAL DISORDER; WOUND CARE; WOUND DRESSING; CHILD; CONJUNCTIVITIS;

CHILD; CONJUNCTIVITIS; EPIDERMAL NECROLYSIS, TOXIC; HUMANS;

EID: 67849124282     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3181a28c82     Document Type: Review

References (142)

1. Jones WG, Halebian P, Madden M, Finkelstein J, Goodwin CW. Drug-induced toxic epidermal necrolysis in children. J Pediatr Surg 1989;24:167-170.
2. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-512.
3. Adzick NS, Kim SH, Bondoc CC, Quinby WC, Remensnyder JP. Management of toxic epidermal necrolysis in a pediatric burn center. Am J Dis Child 1985;139:499-502..
4. Rosenthal AL, Binnick S, Panzer P, Pirozzi DJ. Drug-induced toxic epidermal necrolysis in children. Report of two cases. Cutis 1979;24:437-440.
5. Westly ED, Wechsler HL. Toxic epidermal necrolysis. Gran-ulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984;120:721-726.
6. Marvin JA, Heimbach DM, Engrav LH, Harnar TJ. Improved treatment of the Stevens-Johnson syndrome. Arch Surg 1984;119:601-605.
7. Lyell A. A review of toxic epidermal necrolysis in Britain. Br J Dermatol 1967;79:662-671.
8. Spies M, Sanford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001;108:1162-1168.
9. Avakian R, Flowers FP, Araujo OE, Ramos-Caro FA. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25:69-79..
10. Becker DS. Toxic epidermal necrolysis [see comment]. Lan-cet 1998;351:1417-1420.
11. Rasmussen JE. Erythema multiforme. Should anyone care about the standards of care? [comment]. Arch Dermatol 1995;131:726-729.
12. Smoot EC III. Treatment issues in the care of patients with toxic epidermal necrolysis. Burns 1999;25:439-442.
13. Revuz J, Roujeau JC, Guillaume JC, Penso D, Touraine R. Treatment of toxic epidermal necrolysis. Creteil's experience. Arch Dermatol 1987;123:1156-1158. (Pubitemid 17119308)
14. Goldstein SM, Wintroub BW, Elias PM, Wuepper KD. Toxic epidermal necrolysis. Unmuddying the waters. Arch Derma-tol 1987;123:1153-1156.
15. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153.
16. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necroly-sis. N Engl J Med 1995;333:1600-1607.
17. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-842.
18. Chan HL, Stern RS, Arndt KA, et al. The incidence of ery-thema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-47.
19. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990;126: 1103-1104.
20. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Der-matol 1990;126:37-42..
21. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epi-dermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23:1039-1058.
22. Green D, Law E, Still JM. An approach to the management of toxic epidermal necrolysis in a burn centre. Burns 1993;19: 411-414.
23. Hansen RC. Staphylococcal scalded skin syndrome, toxic shock syndrome, and Kawasaki disease. Pediatr Clin North Am 1983;30:533-544.
24. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble fas ligand. Am J Pathol 2003;162:1515-1520.
25. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8-lymphocyte involvement. Arch Dermatol 1993;129:466-468.
26. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995;131:544-551.
27. Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J Burn Care Rehabil 1997;18:417-420.
28. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002;23:87-96..
29. Sheridan RL, Weber JM, Schulz JT, Ryan CM, Low HM, Tompkins RG. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999;20: 497-500..
30. Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002;109:74-78.
31. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985;13:623-635.
32. Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ. Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987;257:2171-2175.
33. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-1165.
34. Taylor JA, Grube B, Heimbach DM, Bergman AB. Toxic epidermal necrolysis. A comprehensive approach. Multidisciplinary management in a burn center. Clin Pediatr (Phila) 1989;28:404-407.
35. Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-887.
36. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epi-dermal necrolysis disease spectrum. Ophthalmology 1995; 102:1669-1676.
37. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998;102:1018-1022.
38. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002;47: 548-552.
39. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32..
40. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006;27:26-33..
41. Gerdts B, Vloemans AF, Kreis RW. Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre. J Eur Acad Dermatol Venereol 2007;21:781-788.
42. Dore J, Salisbury RE. Morbidity and mortality of mucocuta-neous diseases in the pediatric population at a tertiary care center. J Burn Care Res 2007;28:865-870.
43. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-278.
44. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epi-dermal necrolysis. Dermatology 2003;207:33-36.
45. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-129.
46. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epi-dermal necrolysis: an Asian series. Allergy 2007;62:527-531.
47. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987;123:1166-1170.
48. Yetiv JZ, Bianchine JR, Owen JA Jr. Etiologic factors of the Stevens-Johnson syndrome. South Med J 1980;73: 599-602..
49. Rasmussen J. Toxic epidermal necrolysis. Med Clin North Am 1980;64:901-920.
50. Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol 1979;100:69-86..
51. Kauppinen K. Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulpho-namides. Acta Derm Venereol Suppl (Stockh) 1972;68:1-89..
52. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000;83:347-352.
53. Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995;131:669-672.
54. Rzany B, Schmitt H, Schopf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991;71:171-172.
55. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous drug reactions in patients with AIDS. J Allergy Clin Immunol 1996; 98:1112-1115.
56. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006;6:265-268.
57. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004;123:850-855.
58. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Intern 2006; 55:9-16..
59. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:722-727.
60. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-184.
61. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schopf E. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995;4:313-316.
62. Caproni M, Torchia D, Schincaglia E, et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154:319-324. (Pubitemid 43382704)
63. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-714.
64. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions [see comment]. Br J Der-matol 2005;153:241-253.
65. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109: 155-161.
66. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-1215.
67. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cy-totoxic T-cells in the skin lesions of a patient with toxic epi-dermal necrolysis. J Invest Dermatol 2002;118:728-733.
68. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epider-mal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
69. Posadas SJ, Torres MJ, Mayorga C, Juarez C, Blanca M. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis 2002;29:179-189.
70. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epider-mal necrolysis. J Am Acad Dermatol 2002;47:58-62..
71. Wehrli P, Viard I, Bullani R, Tschopp J, French LE. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000;115:141-148.
72. Arnold R, Seifert M, Asadullah K, Volk HD. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J Immunol 1999;162:7140-7147.
73. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4- and CD8- T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995;155:462-472.
74. Viard-Leveugle I, Bullani RR, Meda P, et al. Intracellular localization of keratinocyte fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 2003; 278:16183-16188.
75. Redondo P, Vicente J, Espana A, Subira ML, De Felipe I, Quintanilla E. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol 1996;135:999-1002..
76. Fleischer AB Jr, Rosenthal DI, Bernard SA, O'Keefe EJ. Skin reactions to radiotherapy-a spectrum resembling erythema multiforme: case report and review of the literature. Cutis 1992;49:35-39.
77. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/ toxic epidermal necrolysis. Br J Dermatol 2006;155:722-728. (Pubitemid 44352552)
78. Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008;29:269-276.
79. Ducic I, Shalom A, Rising W, Nagamoto K, Munster AM. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002;110:768-773.
80. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237-1244.
81. Kamada N, Kinoshita K, Togawa Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol 2006;33:616-622.
82. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005;26:33-41..
83. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-360.
84. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204..
85. Burke JF, Quinby WC, Bondoc CC, Sheehy EM, Moreno HC. The contribution of a bacterially isolated environment to the prevention of infection in seriously burned patients. Ann Surg 1977;186:377-387.
86. Tompkins RG, Burke JF. Burn therapy 1985: acute management. Intensive Care Med 1986;12:289-295.
87. Pirrung MK. Management of toxic epidermal necrolysis. J Intraven Nurs 2001;24:107-112.
88. Calcaterra TC, Strahan RW. Stevens-Johnson syndrome. Oropharyngeal manifestations. Arch Otolaryngol 1971;93:37-41..
89. Kreis BE, Middelkoop E, Vloemans AF, Kreis RW. The use of a PEG tube in a burn centre. Burns 2002;28:191-197.
90. Sheridan RL, Weber JM, Peterson HF, Tompkins RG. Central venous catheter sepsis with weekly catheter change in paediatric burn patients: an analysis of 221 catheters. Burns 1995;21:127-129.
91. Goldstein AM, Weber JM, Sheridan RL. Femoral venous access is safe in burned children: an analysis of 224 catheters. J Pediatr 1997;130:442-446.
92. Kelemen JJ III, Cioffi WG, McManus WF, Mason AD Jr, Pruitt BA Jr. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-278.
93. Anhalt G, Snelling CF. Toxic epidermal necrolysis. Case report. Plast Reconstr Surg 1978;61:905-910.
94. Simons HM. Acute life-threatening dermatologic disorders. Med Clin North Am 1981;65:227-243.
95. Herndon DN. Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids. J Am Coll Surg 1995;180:340-342.
96. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobu-lins and topical conservative approach. A retrospective analysis. Burns 2007;33:452-459.
97. Mittmann N, Chan B, Knowles S, Cosentino L, Shear N. Intravenous immunoglobulin use in patients with toxic epi-dermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006;7:359-368.
98. Kazatchkine MD, Kaveri SV. Immunomodulation of autoim-mune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
99. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005;71:398-400..
100. Trent J, Halem M, French LE, Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg 2006;25:91-93.
101. French LE, Trent JT, Kerdel FA. Use of intravenous immu-noglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immu-nopharmacol 2006;6:543-549.
102. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglob-ulin make a difference? J Burn Care Rehabil 2004;25:81-88.
103. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epider-mal necrolysis. J Burn Care Rehabil 2004;25:246-255.
104. Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002;6: 225-228.
105. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993;21:522-526.
106. Chaidemenos GC, Chrysomallis F, Sombolos K, Mourellou O, Ioannides D, Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36:218-221.
107. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasma-pheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458-461.
108. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plas-mapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985;121:1548-1549.
109. Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 1991;14:634-638.
110. Uchino S, Bellomo R, Goldsmith D, et al. Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med 2002;28:651-655.
111. Paquet P, Pierard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999;198:198-202.. (Pubitemid 29204617)
112. Frangogiannis NG, Boridy I, Mazhar M, Mathews R, Gango-padhyay S, Cate T. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996;89:1001-1003.
113. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol 1991;25:778-786.
114. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-1589.
115. Han J, Thompson P, Beutler B. Dexamethasone and pentoxi-fylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-394.
116. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pen-toxifylline. Biochem Biophys Res Commun 1988;155:1230-1236.
117. Jarrett P, Rademaker M, Havill J, Pullon H. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 1997;22:146-147.
118. Goulden V, Goodfield MJ. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996;135:305-306.
119. Winfred RI, Nanda S, Horvath G, Elnicki M. Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor. South Med J 1999;92:918-920.
120. Lehman SS. Long-term ocular complication of Stevens-Johnson syndrome. Clin Pediatr (Phila) 1999;38:425-427.
121. Kobayashi A, Yoshita T, Sugiyama K, et al. Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement. Ophthalmology 2006;113:126-132.
122. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 2005;112:904-912.
123. John T, Foulks GN, John ME, Cheng K, Hu D. Amniotic membrane in the surgical management of acute toxic epider-mal necrolysis. Ophthalmology 2002;109:351-360.
124. Kozarsky AM, Knight SH, Waring GO III. Clinical results with a ceramic keratoprosthesis placed through the eyelid. Ophthalmology 1987;94:904-911.
125. Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pem-phigoid and Stevens-Johnson syndrome. Am J Ophthalmol 1996;122:38-52..
126. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Oph-thalmol 2008;145:438-444.
127. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye 2005;19:846-853.
128. Imahara SD, Holmes JH IV, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res 2006;27:270-275.
129. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necroly-sis patients treated in a burn center. J Burn Care Res 2008; 29:141-146.
130. de Felice GP, Caroli R, Autelitano A. Long-term complications of toxic epidermal necrolysis (Lyell's disease). Clinical and histopathologic study. Ophthalmologica 1987;195:1-6..
131. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol 1973;90:376-379.
132. Edell DS, Davidson JJ, Muelenaer AA, Majure M. Unusual manifestation of Stevens-Johnson syndrome involving the respiratory and gastrointestinal tract. Pediatrics 1992;89:429-432.
133. Minamihaba O, Nakamura H, Sata M, et al. Progressive bronchial obstruction associated with toxic epidermal necrolysis. Respirology 1999;4:93-95.
134. Schonheyder H. Stevens-Johnson syndrome associated with intrahepatic cholestasis and respiratory disease: a case report. Acta Derm Venereol 1981;61:171-173.
135. Virant FS, Redding GJ, Novack AH. Multiple pulmonary complications in a patient with Stevens-Johnson syndrome. Clin Pediatr (Phila) 1984;23:412-414.
136. Yatsunami J, Nakanishi Y, Matsuki H, et al. Chronic bron-chobronchiolitis obliterans associated with Stevens-Johnson syndrome. Intern Med 1995;34:772-775.
137. McIvor RA, Zaidi J, Peters WJ, Hyland RH. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996;17:237-240.
138. Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998;91:283-287.
139. Wilkins J, Morrison L, White CR Jr. Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Clin 1992;10:571-582.
140. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007;91:1048-1053.
141. Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology 1988;95:453-462.
142. Chan LS, Soong HK, Foster CS, Hammerberg C, Cooper KD. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA 1991;266:1543-1546.